Table 1.
Boron biodistribution and physical radiation doses delivered to tumor, brain, and blood in RG2 glioma bearing rats
| Group‡ | Boron uptake, μg/g wt |
Physical dose, Gy† |
|||||
|---|---|---|---|---|---|---|---|
| Tumor | Brain§ | Blood | Tumor/brain conc. ratio | Tumor | Brain | Blood | |
| RG2/CED N5–2OH | 27.6 ± 9.5 | 2.6 ± 2.4 | <0.5 | 10.6 | 8.1 | 2.3 | 1.9 |
| RG2/CED N5–2OH + i.v. BPA | 45.6 ± 14.1 | 7.3 ± 1.0 | 7.6 ± 1.9 | 6.2 | 12.2 | 3.4 | 3.5 |
| RG2/i.v. BPA | 14.2 ± 7.7 | 5.0 ± 1.0 | 7.5 ± 2.1 | 1.9 | 5.0 | 2.9 | 3.5 |
| RG2/Irradiation control (CED of DMSO) | None | None | None | — | 1.8 | 1.8 | 1.8 |
| RG2/Untreated control (CED N5–2OH) | 17.3 ± 4.3 | <0.5 | <0.5 | 0 | 0 | 0 | |
Boron-10 enriched N5–2OH was administered i.c. by means of convection enhanced delivery over 24 h using Alzet pumps at a flow rate of 8.33 μl/h. BPA was administered intravenously 2.5 h prior to BNCT.
*Boron content was quantified by means of direct current plasma-atomic emission spectroscopy (DCP-AES) and has been reported as micrograms per gram of wt.
†Physical dose estimates include contributions from γ photons, 14N (n,p)14C, and 10B (n,α) 7Li reactions.
‡RG2 glioma cells were implanted into rats intracerebrally. The rats were irradiated 14 days after implantation.
§Boron concentrations for the tumor bearing cerebral hemisphere after excision of the tumor.